Trial Profile
A phase II study of PS341 alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction (GEJ) or stomach
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Feb 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Irinotecan
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 14 Jun 2008 Status changed from recruiting to in progress, as reported by ClinicalTrials.gov.
- 16 Nov 2006 Status change
- 31 Oct 2006 Status change